Immunotherapy belongs to the group of targeted therapies; it is based on natural immune mechanisms which axis can be promoted or blocked at appropriate points. Breast cancer is the world’s most common cancer among women and in March 2019 the FDA approved the first immunopharmaceutical Atezolizumab, for the treatment of breast cancer. So far, the only registered marker for classification for checkpoint inhibitor therapy has been the presence of PD-L1 receptor expression in tumour cells. A comprehensive search of the literature to elucidate the correlation between PD-1/PD-L1 single nucleotide polymorphism (SNP) and cancer, especially breast cancer or other diseases susceptibility and PD-1/ PD-L1 expression. Seven susceptibility loci was considered: rs41386349, rs7421861, rs36084323, rs11568821, rs2227981, rs10204525, rs2227982. Three of them may be taken into account as potentially helpful in breast cancer patient treatment tailoring: rs36084323, rs2227981, rs2227982.